20-F: BGM Group Ltd. Files Annual Report on Form 20-F

BGM Group Ltd. has filed its annual report on Form 20-F for the fiscal year ended September 30, 2025, detailing its financial performance, business operations, and risk factors.

Summary

• BGM Group Ltd. (formerly Qilian International Holding Group Limited) filed its annual report on Form 20-F for the fiscal year ended September 30, 2025.
• The company, incorporated in the Cayman Islands, conducts its operations in China through a variable interest entity (VIE) structure, primarily Gansu Qilianshan Pharmaceutical Co., Ltd. (Gansu QLS).
• BGM Group Ltd. has a diversified business focus, including biopharmaceuticals (oxytetracycline API, crude heparin sodium, licorice preparations), AI applications, intelligent robots, and cloud computing.
• The company reported a net revenue of $37.92 million for the fiscal year ended September 30, 2025, an increase of 51% from the previous year, driven by new AI solutions and insurance business segments.
• However, the company reported a net loss attributable to BGM Group Ltd. of $19.94 million for the fiscal year ended September 30, 2025, a significant increase from a net loss of $1.44 million in the prior year.
• The company faces substantial risks related to its VIE structure, PRC regulations, potential delisting from Nasdaq due to auditor inspection issues, and significant operational challenges in its biopharmaceutical segment, particularly with heparin products.
• The company's Class A ordinary shares are listed on the Nasdaq Capital Market under the symbol BGM, but it received a deficiency letter from Nasdaq for not meeting the minimum bid price requirement.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to the significant increase in net loss, rising operating expenses, declining gross margin in its core segment, and the Nasdaq minimum bid price deficiency, despite revenue growth from new segments.

Positives

• Net revenue increased by 51% to $37.92 million for the fiscal year ended September 30, 2025, compared to $25.10 million in the prior year.
• The company launched new revenue streams in AI Solutions ($3.36 million) and Insurance Business ($10.96 million) due to recent acquisitions.
• Gross profit increased by 53% to $6.31 million, with a gross margin of 17% for the fiscal year ended September 30, 2025, up from 16% in the prior year.
• The company has a strong intellectual property portfolio with 21 issued patents in China for Gansu QLS and 8 for Chengdu QLS, with several pending applications.

Negatives

• Net loss attributable to BGM Group Ltd. increased significantly to $19.94 million for the fiscal year ended September 30, 2025, from $1.44 million in the prior year.
• Selling, general and administrative, and research and development expenses increased by 304% to $18.89 million.
• The company's diversified pharmaceutical and allied products segment saw a 6% decrease in net revenue, with a decline in gross margin from 16% to 11%.
• The company received a deficiency letter from Nasdaq for failing to meet the minimum bid price requirement, with a compliance period until October 21, 2026.
• The company's VIE structure presents significant legal and operational risks, including potential government intervention and enforceability issues of contractual arrangements.
• The company's auditors, ZH CPA, LLC and Enrome LLP, are located in Denver, Colorado and Singapore, respectively, and have been inspected by the PCAOB, but the company remains subject to risks related to foreign auditor inspections.
• The company has a history of net losses and negative EBITDA, with EBITDA for the year ended September 30, 2025 being a loss of $18.56 million.

Risks

• The company's VIE structure is subject to substantial uncertainties regarding the interpretation and application of PRC laws and regulations, which could lead to severe penalties or relinquishment of interests in operations.
• The company's Ordinary Shares may be delisted from Nasdaq if the PCAOB is unable to inspect auditors located in China, as mandated by the Holding Foreign Companies Accountable Act.
• Changes in PRC laws and regulations, including those related to data security, cybersecurity, and foreign investment, could materially and adversely affect the company's business operations.
• The company faces significant competition in its operating industries, which are experiencing rapid technological change.
• The company's pharmaceutical business is subject to inherent risks related to product liability and personal injury claims, and it does not carry product liability insurance.
• A significant portion of the company's revenue is concentrated in a few large customers, and the company does not have long-term agreements with these key customers.
• The company sources raw materials from a limited number of suppliers, and losing one or more suppliers could disrupt operations.
• The company's ability to continue listing on U.S. exchanges could be jeopardized if it is denied permission from Chinese authorities in the future.

Future Outlook

The company plans to continue developing its business by expanding its marketing network and investing in pharmaceutical and chemical facilities, which depends heavily on sufficient capital. If the company cannot obtain equity or debt financing, it may not be able to execute its development and expansion plans, which could have a material adverse effect on its future business performance and operating results.

Management Comments

• The company's management believes that EBITDA is a useful performance measure that facilitates comparison of operating performance on a consistent basis and provides a more complete understanding of factors and trends affecting its business.
• Management believes that the company has sufficient funds to meet its working capital requirements and debt obligations for at least the next twelve months, but acknowledges that there is no assurance of success.
• The company's management has concluded that its disclosure controls and procedures were not effective as of September 30, 2025, due to identified material weaknesses.

Industry Context

StockSavvy.ai notes that BGM Group Ltd.'s diversification into AI Solutions and Insurance Business through acquisitions in 2025 reflects a broader trend among companies in traditional sectors to leverage technology for growth and new revenue streams. However, the significant increase in net loss and the ongoing challenges in the biopharmaceutical segment, coupled with Nasdaq listing concerns, present considerable headwinds.

Comparison to Industry Standards

• The company's net loss of $19.94 million for the fiscal year ended September 30, 2025, is a significant concern when compared to industry peers in the biopharmaceutical sector, many of which are focused on profitability or clear paths to it.
• The 304% increase in Selling, General and Administrative, and Research and Development expenses, while potentially indicative of investment in growth, is substantial and warrants close monitoring against industry benchmarks for R&D spending as a percentage of revenue.
• The decline in gross margin for the core biopharmaceutical segment from 16% to 11% is unfavorable and suggests potential issues with cost management or pricing power compared to industry standards.

Legal Proceedings

• The company is not currently involved in any material legal or administrative proceedings.
• The company may from time to time be subject to various legal or administrative claims and proceedings arising in the ordinary course of business.

Related Party Transactions

• For the year ended September 30, 2025, Chengdu Qilian Trading Co., Ltd. acquired a 25% ownership interest in Caihou Capital (Shenzhen) Group Co., Ltd. for RMB25,000,000, with the full amount paid in 2025.
• As of September 30, 2025, the company had an advance from affiliated company Ahanzhai Development Co., Ltd. for $853,130, which is due on demand.

Stakeholder Impact

• Shareholders may experience substantial losses due to the volatility of the company's Ordinary Shares and the potential delisting from Nasdaq.
• Investors face risks associated with the VIE structure and potential PRC government intervention, which could significantly impact the value of their investment.
• Employees are subject to PRC labor laws and social security regulations; the company has noted non-compliance with social insurance and housing fund contributions for some employees.
• Suppliers may face risks if the company's financial performance deteriorates, potentially impacting payment terms or order volumes.

Next Steps

• Regain compliance with Nasdaq's minimum bid price requirement by ensuring the closing bid price of Class A ordinary shares is at least $1.00 for a minimum of 10 consecutive business days.
• Continue to monitor and address cybersecurity risks and implement robust data protection measures.
• Manage operational costs and improve profitability in the biopharmaceutical segment.
• Successfully integrate acquired AI Solutions and Insurance Business segments to realize expected synergies and growth.
• Continue to navigate the complex regulatory environment in China and comply with all applicable laws and regulations.

Key Dates

Recommendation

The company's significant increase in net loss, coupled with a substantial rise in operating expenses and a decline in gross margin for its core biopharmaceutical segment, presents a deteriorating financial picture. Furthermore, the Nasdaq minimum bid price deficiency poses a material risk of delisting. The company's reliance on a VIE structure in China also introduces regulatory and operational uncertainties. Given these factors, a sell recommendation is warranted.

Keywords

BGM Group Ltd, Form 20-F, Annual Report, SEC Filing, Biopharmaceuticals, AI Solutions, VIE Structure, China Regulations